Retatrutide Will Not Reach the FDA Until Early 2027, Leaving No Price and No Coverage Decision to Point To

Retatrutide has produced some of the largest weight loss figures ever reported in obesity trials. The second is review, which typically runs several months to roughly a year after the FDA accepts an application, placing a plausible decision in late 2027 or 2028. The Coverage Environment It Would Enter Is RestrictiveEven a smooth approval would land in a market where obesity medicines are frequently excluded. Retatrutide is already being sold illegally online, and the FDA has warned against unapproved GLP-1 products that name retatrutide specifically. Approval would follow a review of several months to about a year, placing availability in late 2027 at the earliest.